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We tested whether leptin can ameliorate diabetes
independent of weight loss by defining the lowest
dose at which leptin treatment of ob/ob mice reduces
plasma glucose and insulin concentration. We found
that a leptin dose of 12.5 ng/hr significantly lowers
blood glucose and that 25 ng/hr of leptin normalizes
plasma glucose and insulin without significantly
reducing body weight, establishing that leptin exerts
its most potent effects on glucose metabolism. To
find possible mediators of this effect, we profiled liver
mRNA using microarrays and identified IGF Binding
Protein 2 (IGFBP2) as being regulated by leptin with
a similarly high potency. Overexpression of IGFBP2
by an adenovirus reversed diabetes in insulin-resis-
tant ob/ob, Ay/a, and diet-induced obese mice, as
well as insulin-deficient streptozotocin-treated mice.
Hyperinsulinemic clamp studies showed a 3-fold
improvement in hepatic insulin sensitivity following
IGFBP2 treatment of ob/ob mice. These results
show that IGFBP2 can regulate glucose metabolism,
a finding with potential implications for the pathogen-
esis and treatment of diabetes.
INTRODUCTION
Leptin treatment effectively corrects hyperglycemia and hyperin-
sulinemia in leptin-deficient mice and humans (Farooqi et al.,
1999; Montague et al., 1997; Muzzin et al., 1996; Pelleymounter
et al., 1995; Yu et al., 2008). In humans, leptin is also a highly effec-
tive therapy for the diabetes associated with lipodystrophy, where
it ameliorates the insulin resistance, diabetes, and hepatic steato-
sis associated with this condition. Leptin also improves insulin
resistance in other settings, including patients with Rabson-Men-
denhall syndrome, caused by insulin receptor mutations, suggest-
ing that leptin might act downstream of the insulin receptor in lep-
tin-sensitive individuals. This possibility is supported by numerous
studies in animals showing that leptin can improve insulin resis-
tance in animals with induced mutations or drugs that interfereCwith insulin signal transduction (Asilmaz et al., 2004; Cochran
et al., 2004; Ebihara et al., 2001, 2007; Hill et al., 2009; Morton
et al., 2005). Previous studies have also shown an acute effect of
leptin to increase glucose metabolism in wild-type and ob mice
(Burcelin et al., 1999; Kamohara et al., 1997). The evidence further
suggests that these effects of leptin on glucose metabolism are
mediated indirectly via its actions on specific subpopulations of
neurons in the hypothalamus (Akirav et al., 2004; Asilmaz et al.,
2004; Barzilai et al., 1997; Cohen et al., 2001; Gutie´rrez-Jua´rez
et al., 2004; Hill et al., 2009; Liu et al., 1998; Obici et al., 2001; Ros-
setti et al., 1997; van de Wall et al., 2008). However, the effector
mechanisms by which CNS efferent pathways regulate insulin
sensitivity and hepatic glucose output are largely unknown.
In this report, we set out to explore this mechanism. However,
studies of the effect of leptin on glucose metabolism are compli-
cated by the fact that leptin also causes marked weight loss,
which by itself can improve diabetes. Thus, we first defined the
lowest dose of leptin that could correct insulin resistance and
diabetes and identified two low doses at which an infusion of
leptin corrected hyperglycemia without normalizing food intake
or reducing body weight. Transcription profiles from the livers
of ob/ob mice treated with these doses identified several lep-
tin-regulated genes, including IGF Binding Protein 2 (IGFBP2),
which were significantly induced even by the lowest dose of
leptin (12.5 ng/hr subcutaneously), a dose that does not signifi-
cantly raise the plasma leptin level. IGFBP2 is a plasma protein
and one of six homologous proteins that can bind to IGFs.
IGFBPs are generally thought to inhibit the action of IGFs through
high-affinity binding that prevents interaction with IGF receptors
(Dunger et al., 2004; Firth and Baxter, 2002; Kelley et al., 1996,
2002; Rosenzweig, 2004). A loss of IGF-1 is known to cause dia-
betic-like symptoms, as is overexpression of IGFBP1 (Crossey
et al., 2000; Di Cola et al., 1997; Froesch et al., 1996; Guler
et al., 1987; Kovacs et al., 1999; Rajkumar et al., 1999; Sadri
and Lautt, 2000; Zenobi et al., 1994).
It has been suggested that IGFBP2 also inhibits IGF-1 (Di Cola
et al., 1997; Firth and Baxter, 2002; Kelley et al., 1996; Kovacs
et al., 1999; Sadri and Lautt, 2000). If true, this predicts that over-
expression of IGFBP2 should worsen diabetes in ob/ob mice;
however, this was inconsistent with the finding that IGFBP2 is
induced by a low dose of leptin that improves diabetes and
raised the possibility that it could have the opposite effect. Weell Metabolism 11, 11–22, January 6, 2010 ª2010 Elsevier Inc. 11
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Figure 1. Low-Dose Leptin Treatment of ob/ob Mice Corrects Blood Glucose and Hyperinsulinemia Independently of Body Weight
(A) Mice receiving 12 day leptin treatment; percent change in body weight during treatment. Arrows show days 4 and 8 of treatment. Mice were fasted for 6 hr prior
to receiving anesthesia and blood collection at days 0, 4, 8, and 12. Dose of leptin is as indicated in (A). For each group, nR 4. Dotted line indicates food-restricted
animals (see Figures 3A–3D).
(B) Food intake in grams each day during treatment. Dotted line indicates food-restricted animals (see Figures 3A–3D).
(C–E) Plasma leptin (ng/ml), blood glucose (mg/dl), and plasma insulin (ng/ml) at day 12 of leptin treatment. Blood glucose and plasma insulin for food-restricted
animals can be found in Figures 3C and 3D. Error bars show SEM. *p < 0.05, **p < 0.01.
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Leptin-Regulated IGFBP2 Corrects Diabetesthus considered that acute overexpression of IGFBP2 could
improve glucose metabolism. We tested this using a recombi-
nant adenovirus, which, under the conditions of these studies,
was only expressed in liver, its normal site of expression. Here,
we report the effects of acute IGFBP2 overexpression on
glucose metabolism in leptin-deficient ob/ob, normal, diet-
induced obese (DIO), and Ay type 2 diabetic mice, which are
leptin resistant and insulin resistant, as well as in type 1 diabetic
mice after treatment with streptozotocin (STZ).
RESULTS
Low-Dose Leptin Treatment of ob/ob Mice Corrects
Hyperglycemia and Hyperinsulinemia Independently
of Body Weight
We performed a dose-response study of leptin treatment with
the goal of finding a specific low dose of leptin that does not12 Cell Metabolism 11, 11–22, January 6, 2010 ª2010 Elsevier Inc.reduce weight and food intake but that ameliorates diabetes.
Osmotic pumps were implanted subcutaneously in ob/ob mice
with increasing doses of leptin: 0, 12.5, 25, 50, and 100 ng/hr lep-
tin for 12 days. Daily weight and food intake were measured
(Figures 1A and 1B). At 0, 4, 8, and 12 days, mice were fasted
for 6 hr and anesthetized, and blood was drawn. (The phle-
botomy procedure resulted in a modest weight loss in all of the
groups.)
As expected, mice receiving the highest doses of leptin, 50
and 100 ng/hr, showed a significant decrease in food intake
and body weight with normalization of plasma glucose and
insulin. A dose of 25 ng/hr of leptin also normalized plasma
glucose and insulin, despite the fact that these animals failed
to lose weight during the course of the experiment. This dose
resulted in a steady-state plasma leptin concentration of
0.7 ng/ml, which is minimally above background. Finally, a leptin
dose of 12.5 ng/hr, which fails to increase plasma leptin above
Cell Metabolism
Leptin-Regulated IGFBP2 Corrects Diabetesbackground levels, significantly reduced plasma glucose levels
from 400 ng/ml to 208 ng/ml, p < 0.05. This dose did not signif-
icantly reduce either daily food intake or body weight. As a further
control for this and subsequent studies, we food restricted ob/ob
mice to less than 4 g of food/day, which is less than the food
consumed by animals receiving the 12.5, 25, and 50 ng/hr doses
of leptin. These food-restricted animals failed to show any signif-
icant improvement in plasma glucose or insulin (Figures 1A, 1B,
and S3F; see below).
These results identify two very low doses of leptin that either
correct (25 ng/hr) or improve (12.5 ng/hr) diabetes without
causing the animals to lose weight during the treatment. These
data indicate that, for those parameters studied, the potency
of leptin is greatest for plasma glucose. In an effort to establish
the mechanism responsible for this effect of leptin, we next set
out to identify genes that were significantly regulated by leptin
at the 12.5 and 25 ng/hr doses.
Leptin Regulation of IGFBP2
We hybridized liver RNA prepared from animals receiving
12 days of 0, 12.5, or 25 ng/hr leptin to generate transcriptional
profiles using Illumina microarrays. The aggregate results for
gene expression for each of these experiments are provided
(Figure S1). Data were analyzed by generating an ordered list
of induced genes and comparing the levels of gene expression
in liver RNA prepared from the animals treated with 25 and
12.5 ng/hr of leptin to the PBS control mice. For the 25 ng/hr
group, the two most significantly induced genes were Serpina1e,
a protease inhibitor, and MUP, a testosterone-sensitive urinary
protein. The third most prominently induced gene on this list
was IGFBP2, a plasma protein with IGF-binding activity. IGFBP2
has been shown to inhibit IGF activity in some assays, though its
precise biologic function is unknown (Firth and Baxter, 2002;
Kelley et al., 1996). IGFBP2 was upregulated 5.28-fold at the
25 ng/hr leptin dose (p < 0.01) and 1.6-fold in the 12.5 ng/hr
mice compared to PBS controls (p < 0.01) (Figure S1).
We also used a Taqman assay to confirm that IGFBP2 mRNA
was regulated by leptin. IGFBP2 mRNA levels were upregulated
2-fold in the 12.5 ng/hr mice compared to controls (0.6 versus
0.2, p = 0.11), 3-fold in 25 ng/hr mice (0.9 versus 0.2, p < 0.05),
10-fold in 50 ng/hr mice (2.7 versus 0.2, p < 0.05), and 13-fold
in 100 ng/hr mice (3.2 versus 0.2, p < 0.05) (Figure 2A).
The effect of leptin treatment on plasma levels of IGFBP2 was
measured using an enzyme immunoassay (EIA). IGFBP2 circu-
lates at a level of 396 ng/ml in wild-type mice, and its baseline
levels are significantly reduced in ob/ob, to 31 ng/ml, p < 0.01
(Figures 2B and 2C). Leptin significantly increased plasma
IGFPB2 levels in ob/ob mice by the 4th day of treatment, with
the 100 ng/hr leptin dose increasing it 8-fold by the 12th day
(246 versus 31 ng/ml in ob/ob mice, p < 0.01). Earlier time points
were not examined. IGFBP2 levels increased 4.3-fold in the
25 ng/hr group (132 versus 31 ng/ml in ob/ob mice, p < 0.01)
by the 12th day. There was also a similar trend toward increased
levels of IGFBP2 in the 12.5 ng/hr group (Figure 2B).
Because low doses of leptin markedly improve insulin sensi-
tivity, we considered the possibility that the leptin-mediated
induction of IGFBP2 was insulin dependent. We tested this
possibility in two ways. First, ob/ob mice were severely food
restricted (0.5 g/day for 12 days: this is the voluntary food intakeCof ob/ob mice receiving 200 ng/hr leptin), which resulted in
insulin levels falling by 90%. Despite this reduction in plasma
insulin, plasma IGFBP2 remained constant between food-
restricted mice and controls (35 ng/ml in food-restricted versus
34 ng/ml eating ad libitum, p > 0.7) (Figure 2C). We further exam-
ined the relationship between insulin levels and IGFBP2 expres-
sion by injecting wild-type animals with a bolus of insulin and
found that an acute injection of insulin failed to increase plasma
IGFBP2 levels at 1 and 3 hr postinjection (Figures S3D and S3E).
Consistent with these results, the baseline levels of IGFBP2 were
similar among several different animals with markedly different
baseline levels of insulin, including wild-type mice, type 1 dia-
betic mice resulting from STZ treatment, and Ay and DIO mice,
as well as Srebp-1c diabetic mice (Figure 2C; see below).
Ad-IGFBP2 Treatment Corrects Hyperglycemia,
Hyperinsulinemia, and Hepatic Steatosis in ob/ob
Diabetic Mice
We next tested whether overexpression of IGFBP2 can correct
hyperglycemia and hyperinsulinemia in diabetic mice. A mouse
IGFBP2cDNA was cloned into an empty shuttle adenoviral vector
under the control of the cytomegalovirus (CMV) promoter. This is
a gutless adenoviral vector that does not express adenoviral
genes, thus mitigating secondary effects of the viral infection.
As a control, we used additional adenovirus strains with no inser-
tion or with an insertion of a luciferase reporter. The luciferase
virus allowed us to assess the sites of gene expression from the
viral vector. Five days after intravenous injections of the Ad-lucif-
erase adenovirus, mice received an intraperitoneal injection of
luciferin and were imaged using a CCD camera (IVIS, Caliper
Technology; Hopkinton, MA [previously described in Birsoy
et al., 2008b]). These data showed that viral gene expression
was limited to the liver, a major site of endogenous IGFBP2
expression, and also to the site of injection in the tail (Figure S2A).
Animals injected with the IGFBP2 adenovirus showed a
highly significant increase in plasma IGFBP2 levels, to at least
6000 ng/ml (data not shown). The IGFBP2 and empty (control)
adenoviruses were injected into ob/ob mice, followed by
measures of daily body weight and food intake (Figures 3A and
3B) and plasma glucose and insulin five days after viral injection
(Figures 3C and 3D). Mice treated with the IGFBP2 adenovirus
showed a modest decrease in food intake with a stabilization
of body weight, while the control ob/ob mice continued to gain
weight (Figures 3A and 3B). At 5 days postinjection, the ob/ob
mice that had received the IGFBP2 treatment showed a normal
plasma glucose and insulin. While control mice had blood
glucose levels of over 300 mg/dl, IGFBP2-treated animals had
blood glucose levels under 100 mg/dl (320 versus 94 mg/dl for
the controls, p < 0.01) (Figure 3C). Plasma insulin levels were
also normalized in the IGFBP2-treated mice (85 versus 5 ng/ml,
p < 0.01) (Figure 3D). ob/ob mice pair-fed with the IGFBP2-
treated ob/ob animals failed to show a significant reduction of
blood glucose or plasma insulin (Figures 3A–3D).
We performed glucose tolerance tests (GTTs) in the IGFBP2-
treated mice. While plasma glucose levels of the control
mice peaked above 550 mg/dl at 30 min after glucose injection,
the blood glucose of IGFBP2-treated mice remained below
300 mg/dl (559 versus 288 mg/dl, p < 0.01) (Figure 4A). GTT of
IGFBP2-treated ob/ob mice showed a complete correction ofell Metabolism 11, 11–22, January 6, 2010 ª2010 Elsevier Inc. 13
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Figure 2. Leptin Regulation of IGFBP2
(A) Relative IGFBP2 mRNA expression in liver samples from ob/ob mice leptin treated for 12 days as indicated.
(B) Plasma IGFBP2 levels in ob/ob mice during treatment with leptin at the indicated concentrations.
(C) Plasma leptin (left y axis) and plasma IGFBP2 (right y axis) in mice as follows: WT, wild-type; WT + leptin, wild-type after 8 days of 1 mg/hr leptin; DIO, diet-
induced obese (high-fat diet for 15 weeks); STZ, streptozotocin diabetic; ob/ob mice; ob/ob + leptin, ob/ob after 12 days of 100 ng/hr leptin treatment; ob/ob food
restr., ob/ob after 12 days of food restriction to 0.5 g/day (insulin levels one-tenth of free-feeding: data not shown); Ay, agouti; Srebp-1c. Grey bars indicate
IGFBP2. Black bars indicate leptin levels in same animals. Error bars show standard error. *p < 0.05, **p < 0.01.
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Leptin-Regulated IGFBP2 Corrects Diabetesglucose clearance in response to a glucose challenge (compare
Figure 4A and Figure 5E).
To assess the mechanism of these effects, we utilized hyper-
insulinemic-euglycemic clamps to study insulin sensitivity,
hepatic glucose output, and glucose uptake in treated and
control ob mice. The glucose infusion rates (GIRs) required to
maintain blood glucose levels at 140 mg/dl in these animals
were 3.6-fold higher in the IGFBP2-treated group compared
to controls (36 mg/kg/min in IGFBP2-treated ob/ob versus
10 mg/kg/min in controls, p < 0.01) (Figure 4C), thus showing
a marked effect of IGFBP2 to improve insulin sensitivity. Hepatic14 Cell Metabolism 11, 11–22, January 6, 2010 ª2010 Elsevier Inc.glucose production (HGP) during the insulin clamp of IGFBP2-
treated mice was 11 mg/kg/min, compared to 32 mg/kg/min in
controls (p < 0.01) (Figure 4E). In response to the superphysiolog-
ical 30 mU/kg/min insulin infusion, the HGP was suppressed by
77% of the basal glucose production in IGFBP2-treated ob/ob
mice versus 34% suppression in controls (p < 0.01) (Figure 4F).
In contrast, the glucose disappearance rate (Rd) during the clamp
was not significantly different between IGFBP2-treated and
control ob/ob mice (Figure 4D). We also measured 2-deoxyglu-
cose uptake in white adipose tissue (WAT) and gastrocnemius/
soleus muscle at the end of the clamp. WAT glucose uptake
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Figure 3. IGFBP2 Treatment Corrects Hyperglycemia, Hyperinsulinemia, and Hepatic Steatosis in ob/ob Diabetic Mice
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Leptin-Regulated IGFBP2 Corrects Diabeteswas not affected by IGFBP2 treatment (Figure S3A). Muscle
glucose uptake was slightly increased in IGFBP2-treated ob/ob
relative to wild-type mice, but the difference was not statistically
significant (25 nmol/g/min in IGFBP2-treated versus 17 in con-
trols, p = 0.1) (Figure S3B). Together, these results demonstrate
that IGFBP2 treatment markedly increases insulin sensitivity,
primarily by suppressing hepatic glucose output.
We performed Taqman assays for PEPCK and G6Pase, both
of which regulate hepatic gluconeogenesis. PEPCK wasCreduced 46% (p < 0.01) and G6Pase was reduced 43% (p <
0.05) after Ad-IGFBP2 infection in ob/ob livers (Figure 4B).
These data are consistent with the observation that IGFBP2
suppressed HGP, as shown in the hyperinsulinemic clamp
studies.
The improvement in hepatic insulin sensitivity by IGFBP2
treatment was associated with a significant reduction of
hepatic steatosis. Liver histology showed a drastic reduction
in lipid droplets in the livers of Ad-IGFBP2-treated ob/obell Metabolism 11, 11–22, January 6, 2010 ª2010 Elsevier Inc. 15
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(E) Hepatic glucose production (HGP) in mg/kg/min.
(F) Percent suppression of HGP in response to hyperinsulinemic clamp. In all panels: red, IGFBP2-treated ob/ob mice; blue, control-treated ob/ob mice. *p < 0.05,
**p < 0.01, n = 7. Error bars show standard error.
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Leptin-Regulated IGFBP2 Corrects Diabetesmice (Figure 3F). Liver triglycerides were significantly reduced
by IGFBP2 and also low-dose leptin treatment (Figure 3E).
Consistent with an improvement in hepatic steatosis, fatty
acid synthase (FAS) gene expression was downregulated
32% (p < 0.05) in Ad-IGFBP2-treated livers compared to
controls (Figure 4B).16 Cell Metabolism 11, 11–22, January 6, 2010 ª2010 Elsevier Inc.We next tested the effect of IGFBP2 overexpression in wild-
type mice and other leptin-resistant diabetic mouse strains. In
each case, plasma glucose concentration was significantly
decreased in the animals receiving the IGFBP2 adenovirus.
By the 6th day after IGFBP2 infection, blood glucose in wild-
type mice fell 37% (90 versus 142 mg/dl, p < 0.01); in DIO
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Leptin-Regulated IGFBP2 Corrects Diabetesanimals, blood glucose fell 32% (117 versus 171 mg/dl, p <
0.01), and finally, blood glucose fell 34% in Ay mice (134
versus 202 mg/dl, p < 0.05) (Figure 5A). There was a trend
for reduction in insulin levels in all of these mice, although it
only reached significance in Ay mice (Figure 5B). The levels
of blood glucose during GTTs were also significantly reduced
at all time points, including the peak level in wild-type, Ay,
and DIO mice treated with the IGFBP2 adenovirus versus
controls (Figures 5E–5H). Changes in food intake and body
weight were minimal and, in most cases, not statistically signif-
icant between the experimental and control animals (Figures
5C and 5D).
Ad-IGFBP2 Treatment Corrects Hyperglycemia
in Insulin-Deficient Mice
Previous studies have shown that leptin treatment corrects
hyperglycemia in type 1 diabetic mice (Yu et al., 2008). We
next tested whether IGFBP2 can improve diabetes in this setting
of insulin deficiency. IGFBP2 was injected into STZ-induced
insulin-deficient mice. Plasma insulin was not detectable 6 weeks
after low-dose STZ treatment, even when using an ultrasensitive
mouse insulin EIA kit (Figure 5B and data not shown). At day 5
after IGFBP2 injections, control mice had fasting (4 hr) glucose
levels of 509 compared to 136 mg/dl in the IGFBP2-treated
group (p < 0.01) (Figure 5A). GTTs were also markedly improved
at 45 min (654 versus 342 mg/dl, p < 0.05) (Figure 5G). Food
intake and body weight were not changed in either group
(Figures 5C and 5D).CIGFBP2 Levels in Leptin-Deficient Patients
Finally, we assessed whether IGFBP2 regulation by leptin is
evident in human subjects. To this end, we obtained sera from
three leptin-deficient patients and age- and weight-matched
controls, before and after 6 months of daily subcutaneous low-
dose leptin treatments. These patients and their treatment
have been previously described (Farooqi et al., 2002). There
was a 2-fold decrease in baseline serum IGFBP2 levels in the
leptin-deficient (LEP/LEP) versus control patients (leptin-defi-
cient patients had 71 ng/ml serum IGFBP2 versus 132 ng/ml in
controls, p = 0.04) (Figure 6A). After low-dose leptin treatment,
IGFBP2 levels increased in two out of three patients, from 50
to 88 ng/ml in Patient 1 and from 90 to 132 ng/ml in Patient 2,
while one patient showed no change (74 and 74 ng/ml). The
average levels of IGFBP2 before and after leptin treatment
were 71 ng/ml and 98 ng/ml respectively (p = 0.2) (Figure 6B).
DISCUSSION
Leptin has been shown to improve hyperglycemia and insulin
resistance in a number of clinical settings in animals and
humans. These conditions include leptin mutations, lipodystro-
phy, and Rabson-Mendenhall syndrome, resulting from insulin
receptor mutations (Asilmaz et al., 2004; Chinookoswong et al.,
1999; Farooqi and O’Rahilly, 2004; Montague et al., 1997; Oral
et al., 2002; Petersen et al., 2002; Shimomura et al., 1999; Yu
et al., 2008). More recently, leptin has been shown to markedly
improve the metabolic abnormalities of type 1 diabetic nonobeseell Metabolism 11, 11–22, January 6, 2010 ª2010 Elsevier Inc. 17
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Figure 6. IGFBP2 Levels in Leptin-Deficient
Patients
(A) Serum IGFBP2 in leptin-deficient and age- and
weight-matched controls.
(B) Serum IGFBP2 in three leptin-deficient patients
before (light gray) and 6 months after (dark gray)
low-dose leptin treatment. Error bars show stan-
dard error.
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Leptin-Regulated IGFBP2 Corrects Diabetesdiabetic (NOD) mice, which have a complete insulin deficiency
(Yu et al., 2008). The mechanism by which leptin exerts these
salutary effects is poorly understood. In this report, we sought
to explore the mechanism responsible for leptin’s antidiabetic
effects and first showed that leptin infusions can correct
diabetes of ob/ob mice at low doses that do not result in weight
loss. IGFBP2 gene expression is induced by these low doses
of leptin treatment, and IGFBP2 plasma levels increase in
response to leptin treatment of ob/ob and wild-type mice. Over-
expression of IGFBP2 using a recombinant adenovirus resulted
in a striking reduction of plasma glucose and insulin in all animals
tested, including ob/ob, wild-type, Ay, DIO, and STZ-treated
animals. Overall, these data confirm that leptin can improve
glucose homeostasis independent of its ability to reduce weight
and suggest that IGFBP2 may account for a portion of leptin’s
antidiabetic effects.
IGFBP2 is a 34 kDa plasma protein produced by liver. It was
originally isolated based on its ability to bind to IGF-1 and IGF2
and is one of six IGF-binding proteins that circulate in plasma
(Baxter and Martin, 1989; Kelley et al., 2002; Martin and Baxter,
1986). Further studies in vitro suggested that IGFBP2 and the
other IGFBPs function as IGF inhibitors by chelating these
ligands (Arai et al., 1996; Ho¨flich et al., 1998; Jones and Clem-
mons, 1995). However, IGFBP2 circulates at equimolar or lower
molar concentrations compared to IGF-1, which is not a typical
characteristic of hormone inhibitors that generally circulate in
molar excess of the ligand. In vivo, IGFBP2 has been invoked
as playing a role to modulate IGF signaling in growth and devel-
opment, cancer, and diabetes. The precise function of IGFBP2 is
poorly understood, and it is not well established whether it
inhibits or activates IGF-1 signaling in vivo or if it has actions
independent of IGF (Arai et al., 1996; Russo et al., 2005; Wolf
et al., 2000). (These possibilities are not mutually exclusive.)
An IGFBP2 knockout does not have a major metabolic pheno-
type, and it as been suggested that other IGFBPs can compen-
sate for its loss (Pintar et al., 1995; Wood et al., 1993). However,
a possible role for IGFBP2 in the regulation of metabolism has
been suggested by its association to diabetes in several human
whole-genome studies (Cauchi et al., 2008a, 2008b; Grarup
et al., 2007; Hertel et al., 2008; Horikawa et al., 2008; Sanghera
et al., 2008; Saxena et al., 2007; Scott et al., 2007; Zeggini et al.,18 Cell Metabolism 11, 11–22, January 6, 2010 ª2010 Elsevier Inc.2007). In addition, a human CMV-IGFBP2
transgene (expressed in brain, kidney,
ovaries, and uterus) has been shown to
modestly prevent weight gain and hyper-
glycemia in DIO mice. However, in that
report, it was not shown whether the
effect of IGFBP2 on diabetes was inde-
pendent of its effect on body weight, norwas the potential therapeutic benefit of acute IGFBP2 overex-
pression established (Wheatcroft et al., 2007).
The results reported here show an ability of IGFBP2 to
profoundly reduce plasma glucose and insulin when acutely
overexpressed from an adenoviral vector in wild-type and
ob/ob mice, as well as in markedly hyperglycemic STZ-induced
insulin-deficient (type 1 diabetic) mice and even in leptin-resis-
tant DIO and Ay mice, both of which have type 2 diabetes (Lin
et al., 2000; Prpic et al., 2003; Van Heek et al., 1997). Thus,
IGFBP2 can improve glucose metabolism in leptin-sensitive
and leptin-resistant animals, an observation that is consistent
with the finding that IGFBP2 is regulated by, and thus down-
stream of, leptin signaling. IGFBP2 levels are not higher in DIO
and Ay animals than in wild-type mice, which is consistent with
the fact that they are leptin resistant. The finding that these
leptin-resistant animals still respond to exogenous IGFBP2, simi-
larly to leptin-sensitive animals, is also consistent with IGFBP2
being downstream of leptin’s effects on specific neural popula-
tions in the hypothalamus and elsewhere in the brain (van de
Wall et al., 2008).
In these studies, we used an adenovirus to overexpress
IGFBP2, because this protein has seven disulfides and is difficult
to produce as a recombinant protein in sufficient quantities to
assess its in vivo function. However, adenoviral expression
results in IGFBP2 protein levels that are significantly higher
than the level at which it normally circulates in the blood stream,
and further studies will be required to determine whether the
observed effects are pharmacologic. Efforts to produce bioac-
tive recombinant IGFBP2 and test its effects when administered
at more physiologic levels are underway.
The mechanism by which IGFBP2 reduces blood glucose is
also under investigation. Hyperinsulinemic-euglycemic clamps
show that IGFBP2 markedly improves hepatic insulin sensitivity
in ob/ob mice, with a 3-fold increase in the GIR. However, while
exerting a highly significant effect, IGFBP2 treatment did not
normalize the profoundly (10-fold) depressed insulin sensitivity
of ob mice, suggesting that other mechanisms contribute to
the insulin resistance of leptin-deficient animals (Ahima et al.,
2006; Qi et al., 2006). Consistent with the marked reduction
of HGP, Ad-IGFBP2 lowers expression of the rate-limiting
gluconeogenic enzymes PEPCK and G6Pase. In addition, we
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suggest that IGFBP2 suppresses HGP, at least in part, by down-
regulating transcription of genes involved in hepatic gluconeo-
genesis and hepatic fatty acid synthesis. The improvement in
hepatic insulin sensitivity in IGFBP2-treated ob/ob mice may
be due to a reduction in hepatic steatosis. A similar negative
correlation between hepatic steatosis and insulin sensitivity
has been described in ob/ob mice treated with an insulin-sensi-
tizing aminosterol (Takahashi et al., 2004) or antisense oligonu-
cleotides against the lipid droplet protein ADRP (Imai et al.,
2007). Further studies will be required to determine to what
extent the amelioration of steatosis can account for the benefi-
cial effects of IGFBP2 on HGP. Further studies will also be
necessary to determine whether IGFPB2 improves steatosis
and hepatic insulin sensitivity by an autocrine mechanism or indi-
rectly via modulating the activity of other organs or the levels of
other hormones that regulate glucose metabolism.
Since IGFBP2 does not fully correct HGP, but nonetheless
normalizes plasma glucose, insulin, and a GTT in ob/ob mice,
it is possible that it could also have additional insulin-indepen-
dent effects to reduce blood glucose. This possibility is consis-
tent with the observation that the IGFBP2 adenovirus can also
normalize glucose levels in insulin-deficient STZ mice. While it
is conceivable that IGFBP2 can sensitize these mice to a low
level of residual insulin, it is also possible that IGFBP2 acts
through an insulin- or even IGF-independent mechanism.
The data in this report also establish that the potency of leptin
for reducing hyperglycemia is greater than that for correcting food
intake and body weight. While an early study of leptin showed
direct effects on hyperglycemia independent of weight loss in
ob/ob mice, the study used daily i.p. bolus injections of leptin,
as opposed to the continuous doses used in this study (Pelley-
mounter et al., 1995). In other studies, leptin improved diabetes
to a greater extent than pair-feeding, suggesting that leptin had
independent effects on glucose metabolism (Levin et al., 1996;
Schwartz et al., 1996). Finally, a study of low-dose leptin infusions
to treat diabetic lipodystrophic animals was limited by the fact
that the underlying condition of these animals made it difficult
to assess whether there was significant weight loss (Asilmaz
et al., 2004). Thus, our data confirm that a continuous infusion
of leptin regulates glucose metabolism independent of its effects
on energy balance and identify conditions under which this effect
can be studied without a confounding effect on body weight.
The low doses of leptin used in these studies also reveal
a potent effect of leptin to regulate several liver genes, some of
which could play a role in mediating leptin’s effects. The mech-
anism responsible for the induction of IGFBP2 and these other
genes is as yet unknown. While the data in this paper do not
address whether leptin regulates IGFBP2 as a result of direct
effects on liver versus indirectly by activating CNS efferent
signals from brain to liver, the available evidence supports
the latter possibility, including an earlier report from our labora-
tory showing that IGFBP2 gene expression is upregulated in
response to low-dose i.c.v. leptin treatment in leptin-deficient
lipodystrophic animals (Asilmaz et al., 2004). In this previous
study, the doses of i.c.v. leptin that were used did not elevate
plasma leptin levels, suggesting that leptin can induce IGFBP2
by acting on the brain to activate efferent signals to the
periphery. This conclusion is consistent with previous studiesCshowing that a brain-specific knockout of the leptin receptor
can recapitulate the ob phenotype, while a liver-specific knock-
out had no discernible effect (Cohen et al., 2001). Also consistent
with a CNS site of action for leptin’s effects, a brain-specific
leptin receptor transgene is able to suppress the obesity and dia-
betes of db/db mice (Kowalski et al., 2001). The hypothalamus
has potent effects on glucose metabolism, as shown by the
powerful effect of i.c.v. carbachol, an acetylcholine agonist, to
rapidly stimulate the metabolic clearance of glucose in dogs
(Miles et al., 1991; Vranic et al., 1976). More recently, it has
been shown that alterations in the activation of hypothalamic
K(ATP) channels can alter hepatic glucose output (Pocai et al.,
2005). Finally, a POMC-specific knockout of the leptin receptor
has potent effects on glucose metabolism, suggesting that lep-
tin’s actions on these and perhaps other neurons activate
efferent signals that control glucose metabolism and hepatic
glucose output (Balthasar et al., 2004; Pocai et al., 2005).
The nature of the efferent signals that control glucose metabo-
lism and IGFBP2 gene expression are unknown, and if, as the
evidence suggests, IGFBP2 is regulated by CNS pathways, it
will be of great interest to establish the factor(s) responsible for
its induction. The signal responsible for the leptin-mediated
increase of IGFBP2 is unknown but does not appear to be insulin,
as acute increases or subacute sustained decreases of plasma
insulin concentration do not alter circulating IGFBP2 levels
(Figures S3D, S3E, and 2C). Further studies are necessary to
confirm whether the ability of low-dose leptin to induce IGFBP2
is mediated by efferent neural outputs from the CNS and/or
a result of modulation of its gene expression by other hormones.
Finally, consistent with the mouse data, we found lower
IGFBP2 levels in leptin-deficient human subjects compared to
control subjects and that IGFBP2 levels increased after leptin
treatment in two out of three patients. (Note that the small
number of individuals included in this analysis is a result of the
fact that leptin deficiency is extremely rare; these three patients
represent 10% of such patients worldwide.) Despite the small
size of this study, the data raise the possibility that IGFBP2 could
have therapeutic effects in human diabetes, which in this case
would likely require the use of recombinant protein rather than
a viral vector. A variety of eukaryotic expression systems will
be tested for their ability to yield bioactive IGFBP2.
In summary, we have developed a set of conditions in which
leptin treatment potently improves diabetes independent of its
ability to correct weight and food intake. This protocol was
used to identify IGFBP2 as a leptin-regulated gene whose
expression is correlated with leptin’s antidiabetic effect. IGFBP2
overexpression reduces blood glucose in wild-type and diabetic
mice and potently suppresses HGP, as well as genes involved in
hepatic gluconeogenesis and fatty acid synthesis, suggesting
that IGFBP2 may play a role in mediating some portion of leptin’s
antidiabetic effects. Further studies will reveal whether IGFBP2
shows similar antidiabetic effects in clinical settings.EXPERIMENTAL PROCEDURES
Mice and Diet
Leptin Dose Experiment
Eight-week-old male C57BL/6 Lep-ob/ob mice were obtained from the
Jackson Laboratory (Bar Harbor, ME), acclimated to our mouse facility underell Metabolism 11, 11–22, January 6, 2010 ª2010 Elsevier Inc. 19
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Leptin-Regulated IGFBP2 Corrects Diabetescontrolled light conditions (12 hr light/12 hr dark) and temperature (22C),
single-caged, and fed ad libitum a standard mouse chow for at least a week.
Alzet 2002 mini-osmotic pumps (Alzet; Palo Alto, CA) were filled with indicated
concentrations of leptin (Amgen; Thousand Oaks, CA), incubated at 37C
in sterile 0.9% NaCl overnight, and implanted subcutaneously in 9- to
11-week-old mice. Mice were single-caged, and their weight and food-
intake were recorded daily. At 0, 4, 8, and 12 days of treatment, mice were
anesthetized and blood was collected intraorbitally. At day 12, mice were
anesthetized, and livers were collected and fresh frozen in liquid N2 or fixed
in Accustain Formalin Solution Neutral Buffered 10% Formalin (Sigma-Aldrich;
St. Louis) overnight for histology. All animal protocols were in accordance with
national guidelines and approved by the IACUC.
Ad-IGFBP2 Experiments
Eight-week-old male C57BL/6 Lep-ob/ob or wild-type mice were acclimated
as above. Ay mice were ordered from Jackson Laboratory and kept until at
least 12 weeks of age. Wild-type male mice were ordered from Jackson
Laboratory and kept on a standard high-fat-diet chow until at least 15 weeks
of age. Mice received intrajugular vein injections under anesthesia (isoflurane)
of 1.2 3 1011 particles of Ad-CMV-empty, Ad-CMV-Luciferase or Ad-CMV-
IGFBP2 (ViraQuest Inc.; North Liberty, IA). One week after injections, plasma
levels of IGFBP2 were confirmed with an IGFBP2 EIA kit (Alpco Diagnostics;
Windham, NH).
STZ-Treated Mice
Five-week-old male C57BL/6 wild-type mice were obtained from the Jackson
Laboratory and received a daily intraperitoneal dose of 50 mg/kg STZ (Sigma)
for 5 days. Four weeks later, hyperglycemic mice were injected with Ad-
IGFBP2 as described above.
Metabolic Studies
GTT
Mice were injected intraperitoneally with 1 unit glucose/gram body weight.
Blood glucose was recorded at 0, 30, 60, and 120 min postinjection. In STZ
mice, blood glucose was recorded at 0 and 45 min postinjection.
Hyperinsulinemic-Euglycemic Clamp
This has been previously described in Qi et al., 2006. Ten-week-old male
ob/ob mice were treated with Ad-CMV-IGFBP2 or Ad-CMV-control via a tail
vein injection, and insulin clamp was performed 10 days later. An indwelling
catheter was inserted in the right internal jugular vein under sodium pentobar-
bital anesthesia and extended to the right atrium. After regaining their presur-
gery weight (4 days), the mice were fasted for 6 hr, and a bolus injection of 5 mCi
[3-3H]glucose was administered, followed by continuous intravenous infusion
at 0.05 mCi/min. Baseline glucose kinetics was measured for 60 min. A priming
dose of regular insulin (40 mU/kg, Humulin; Eli Lilly; Indianapolis, IN) was given
intravenously, followed by continuous infusion at 30 mU/kg/min. Blood
glucose was maintained at 120–140 mg/dl via a variable infusion rate of
30% glucose. At the end of the 120 min clamp, 10 mCi 2-deoxy-D-
[1-14C]glucose was injected to estimate glucose uptake. The mice were eutha-
nized, and liver, perigonadal fat (WAT), and gastrocnemius/soleus muscle
were excised, frozen immediately in liquid nitrogen, and stored at 80C for
subsequent analysis of glucose uptake. The rates of basal glucose turnover
and whole-body glucose uptake are measured as the ratio of [3H] GIR (dpm)
to the specific activity of plasma glucose. HGP during clamp is measured by
subtracting the GIR from the whole-body glucose uptake (Rd).
Liver Triglycerides
Liver triglycerides were determined using Sigma TR0100 Triglyceride Determi-
nation Kit.
Human Subjects
Fasting plasma samples were obtained from three children with leptin defi-
ciency before and six months after treatment with recombinant human leptin,
as reported previously (Farooqi et al., 2002). All samples were stored at80C
and thawed once prior to analysis. Results were compared to age- and BMI-
matched controls on whom fasting plasma samples had been obtained.
Real-Time PCR and Microarray
Total RNA was isolated by homogenizing liver tissue in TRIzol reagent (Invitro-
gen) and purifying the RNA using QIAGEN RNA prep kit. Real-time PCR was
performed using the TaqMan system (Applied Biosystems; Foster City, CA)20 Cell Metabolism 11, 11–22, January 6, 2010 ª2010 Elsevier Inc.according to the manufacturer’s protocol, as previously described (Birsoy
et al., 2008a). Microarrays were done using MouseRef-8 v2 BeadChip (part
11288185) after labeling the RNA with Ambion’s Illumina TotalPrep RNA
Amplification Kit.
Serum Assays
Blood glucose was determined using an Ascensia Elite XL glucometer (Bayer;
Leverkusen, Germany) or QuantiChrom Glucose Assay Kit (BioAssay Systems;
Hayward, CA). For all other assays, mice were bled intraorbitally while briefly
anesthetized with minimal isoflourane adjusted to body weight. Blood was
spun for 10 min and plasma was collected. Plasma insulin was determined
using an insulin (mouse) EIA kit (Alpco). Plasma leptin and IGFBP2 levels
were determined using a leptin (mouse/rat) EIA kit and an IGFBP2 (mouse/
rat) EIA kit, respectively (Alpco). Plasma IGF-1 was determined using a mouse
IGF-I Quantikine ELISA Kit (R&D Systems). Ketone bodies were determined
using a Beta-Hydroxybutyrate Assay Kit (Cayman Chemical Company; Ann
Arbor, MI).
Histology
Paraffin-embedded, 10% formalin-perfused livers were sectioned and stained
with hematoxylin and eosin.
Statistical Analysis
All data were analyzed for statistical significance using the Student’s t test.
P values are as indicated.
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